XJPX
4884
Market cap28mUSD
Oct 09, Last price
645.00JPY
1D
17.70%
1Q
94.28%
IPO
-53.26%
Name
Kringle Pharma Inc
Chart & performance
P/E
—
P/S
72.15
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.11%
Rev. gr., 5y
-31.17%
Revenues
72m
-9.77%
Net income
-916m
L+21.13%
CFO
-756m
L+14.31%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
Key people
Kiichi Adachi
President, Chief Executive Officer, Representative Director · since 2016
Yoshiyuki Chino
Director of Reliability Assurance, Director · since 2025
Daishin Hayata
Director of Pharmaceutical Development, Director of Pharmaceutical Affairs, Director · since 2025
Koichi Murakami
Director of Business Administration, Director · since 2021
Akihiro Tomoyasu
Non-Executive Director · since 2025
Masato Fukui
Independent Director · since 2020
Independent Director · since 2018
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||